Targeting HSF1 sensitizes cancer cells to HSP90 inhibition

Oncotarget

Volumn 4, Issue 6, 2013, Pages 816-829

  Chen, Yaoyu ^a   Chen, Jinyun ^a   Loo, Alice ^a   Jaeger, Savina ^a   Bagdasarian, Linda ^a   Yu, Jianjun ^a   Chung, Franklin ^a   Korn, Joshua ^a   Ruddy, David ^a   Guo, Ribo ^a   Mclaughlin, Margaret E ^a   Feng, Fei ^a   Zhu, Ping ^a   Stegmeier, Frank ^a   Pagliarini, Raymond ^a   Porter, Dale ^a   Zhou, Wenlai ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cancer cells; DEDD2; HCC; HSF1; HSP90 inhibitor; Melanoma

Indexed keywords

CHAPERONE; DOXYCYCLINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; RNA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DEDD2 GENE; DRUG MECHANISM; FEEDBACK SYSTEM; GENE; GENE TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN TARGETING; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DNA-BINDING PROTEINS; DOXYCYCLINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; MICE; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880811049     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.991     Document Type: Article

References (42)

1. Wandinger SK, Richter K and Buchner J. The Hsp90 chaperone machinery. The Journal of biological chemistry. 2008; 283(27):18473-18477.
2. Trepel J, Mollapour M, Giaccone G and Neckers L. Targeting the dynamic HSP90 complex in cancer. Nature reviews. 2010; 10(8):537-549.
3. Munster PN, Marchion DC, Basso AD and Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer research. 2002; 62(11):3132-3137.
4. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J and Neckers LM. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Molecular and cellular biology. 1996; 16(10):5839-5845.
5. Stepanova L, Leng X, Parker SB and Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes & development. 1996; 10(12):1491-1502.
6. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE and Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res. 2003; 9(13):4961-4971.
7. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P and Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. The Journal of biological chemistry. 2002; 277(42):39858-39866.
8. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F and Neckers LM. Hsp90 regulates a von Hippel Lindauindependent hypoxia-inducible factor-1 alpha-degradative pathway. The Journal of biological chemistry. 2002; 277(33):29936-29944.
9. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL and Jay DG. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nature cell biology. 2004; 6(6):507-514.
10. Solimini NL, Luo J and Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 2007; 130(6):986-988.
11. Whitesell L and Lindquist SL. HSP90 and the chaperoning of cancer. Nature reviews. 2005; 5(10):761-772.
12. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P and Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2011; 2(3):209-221.
13. Martins AS, Davies FE and Workman P. Inhibiting the molecular evolution of cancer through HSP90. Oncotarget. 2012; 3(10):1054-1056.
14. Subjeck JR and Repasky EA. Heat shock proteins and cancer therapy: the trail grows hotter! Oncotarget. 2011; 2(6):433-434.
15. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L and Trepel JB. Update on Hsp90 inhibitors in clinical trial. Current topics in medicinal chemistry. 2009; 9(15):1479-1492.
16. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, et al. 4,5-diarylisoxazole Hsp90 chaperoneinhibitors: potential therapeutic agents for the treatment of cancer. Journal of medicinal chemistry. 2008; 51(2):196- 218.
17. Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK, Duhl D, Machajewski T, Sellers WR, Pryer NK and Gao Z. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther. 2012; 11(3):730-739.
18. Walsby E, Pearce L, Burnett AK, Fegan C and Pepper C. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget. 2012; 3(5):525-534.
19. Flandrin-Gresta P, Solly F, Aanei CM, Cornillon J, Tavernier E, Nadal N, Morteux F, Guyotat D, Wattel E and Campos L. Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase. Oncotarget. 2012; 3(10):1158-1168.
20. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J and Rosen N. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2009; 29(3):325-334.
21. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N and Chapman PB. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res. 2008; 14(24):8302- 8307.
22. de Billy E, Travers J and Workman P. Shock about heat shock in cancer. Oncotarget. 2012; 3(8):741-743.
23. Pirkkala L, Nykanen P and Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2001; 15(7):1118-1131.
24. Dai C, Whitesell L, Rogers AB and Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell. 2007; 130(6):1005-1018.
25. Whitesell L and Lindquist S. Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert opinion on therapeutic targets. 2009; 13(4):469-478.
26. Jin X, Moskophidis D and Mivechi NF. Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab. 2011; 14(1):91-103.
27. Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H, Bronson RT, Whitesell L and Lindquist S. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest. 2012; 122(10):3742-3754.
28. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ and Whitesell L. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res. 2000; 6(8):3312-3318.
29. Zaarur N, Gabai VL, Porco JA, Jr., Calderwood S and Sherman MY. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer research. 2006; 66(3):1783-1791.
30. Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G and Kern MA. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology. 2009; 50(1):102- 112.
31. Heimberger T, Andrulis M, Riedel S, Stuhmer T, Schraud H, Beilhack A, Bumm T, Bogen B, Einsele H, Bargou RC and Chatterjee M. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol. 2012.
32. Powers MV, Clarke PA and Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer cell. 2008; 14(3):250-262.
33. Behl C. BAG3 and friends: co-chaperones in selective autophagy during aging and disease. Autophagy. 2011; 7(7):795-798.
34. Alcivar A, Hu S, Tang J and Yang X. DEDD and DEDD2 associate with caspase-8/10 and signal cell death. Oncogene. 2003; 22(2):291-297.
35. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L and Lindquist S. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell. 2012; 150(3):549-562.
36. Zajac M, Gomez G, Benitez J and Martinez-Delgado B. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer. BMC medical genomics. 2010; 3:44.
37. Roth W, Stenner-Liewen F, Pawlowski K, Godzik A and Reed JC. Identification and characterization of DEDD2, a death effector domain-containing protein. The Journal of biological chemistry. 2002; 277(9):7501-7508.
38. Conde R, Belak ZR, Nair M, O'Carroll RF and Ovsenek N. Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2009; 87(6):845-851.
39. Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK and Stoeltzing O. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology. 2009; 49(2):523-532.
40. de Billy E, Powers MV, Smith JR and Workman P. Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome. Cell cycle (Georgetown, Tex. 2009; 8(23):3806- 3808.
41. Neznanov N, Gorbachev AV, Neznanova L, Komarov AP,Gurova KV, Gasparian AV, Banerjee AK, Almasan A, Fairchild RL and Gudkov AV. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell cycle (Georgetown, Tex. 2009; 8(23):3960-3970.
42. Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, Chen Y, Caponigro G, Yao YM, Lengauer C, Sellers WR and Benson JD. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell cycle (Georgetown, Tex. 2009; 8(3):498-504.